HOME >> MEDICINE >> NEWS
Passing stop sign cures gene disease

awbacks. The body absorbs it poorly, so it must be injected or inhaled. And inhaling is fine for cystic fibrosis, but of little use for conditions such as muscular dystrophy. The antibiotic can also cause rare but serious side effects such as hearing loss and kidney damage.

That's where PTC124 comes in: it was designed from the start to have similar properties to gentamicin but to be safer and more easily absorbed. "We are really in a different situation now, where we are trying to identify drugs based on how they should act," says Langdon Miller, chief medical officer of PTC Therapeutics in New Jersey.

The drug was screened out of a pool of 175,000 synthetic molecules. Pre-clinical tests so far indicate that it is more potent than gentamicin and seems to have very low toxicity. "This could have very far-reaching effects," claims David Bedwell, a microbiologist at the University of Alabama in Birmingham, who has tested the compound in his lab and is collaborating with the company.

In mice with muscular dystrophy the drug restores expression of the dystrophin protein found on the surface of muscle cells. Tests suggest the muscles regain some of their normal characteristics. Tests on mice with cystic fibrosis also suggest PTC124 restores production of functional CFTR.

All the results remain unpublished, though researchers working with the company say they hope to publish as soon as intellectual property issues are resolved. Miller says the company hopes to start clinical trials with healthy volunteers as early as next year.

But a premature stop mutation will not always be the cause of a particular genetic disease. So even if PTC124 or gentamicin make it to the market for treating genetic diseases, they will not be a magical cure for everyone.


'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
15-Oct-2003


Page: 1 2

Related medicine news :

1. Procedure cures atrial fibrillation
2. First UK cases of previously rare disease reported in gay men
3. Uric acid and heart disease
4. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
5. Risky surgery not always necessary to treat cervical disease
6. Stanford patient is first to test new treatment for peripheral arterial disease
7. Community care tops medical care at preventing heart disease in black Americans
8. Neuronal death and processing of Tau protein in Alzheimers disease
9. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
10. Reducing hostility in young coronary artery disease patients is important piece of rehabilitation
11. Study finds direct association between cardiovascular disease and periodontal bacteria

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Passing stop sign cures gene disease

(Date:8/22/2014)... intensive effort to sterilize feral cats reduced the number of ... a new study reveals. "We investigated whether we ever ... control," Dr. Julie Levy, a professor of shelter medicine at ... a university news release. "Neutering a few cats ... "so we wanted to pick a focused area and throw ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 A national leader ... into new offices with room to grow. , Headquarters for ... to a 60,000-square-foot office building at 8516 N.W. Expressway in ... named one of the Oklahoma’s best places to work by ... The company has hired 120 in the past two years, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Home ... of in-home care for seniors, is proud to announce ... Series. The upcoming webinar will feature Dr. Suzanne Steinbaum, ... Lenox Hill Hospital in New York City, National Spokesperson ... author. The webinar will cover the issues surrounding women ...
(Date:8/22/2014)... (HealthDay News) -- Inner city children have a higher-than-normal risk ... followed 516 inner city children in four U.S. cities -- ... until age 5 and found that at least 10 percent ... Because only the three most common types of food ... inner city youngsters with food allergies may be even higher, ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
Breaking Medicine News(10 mins):Health News:Neutering Project Curbed Feral Cat Population 2Health News:Fast-growing 180 Medical Moves Into New 60,000-square-foot Office in Oklahoma City 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... COPD,  physicians in Brazil ... follow clinical guidelines and commonly prescribe long-acting beta-agonist ... although they do so within current severe cost/coverage ... (FDCs) that are expected to launch in these ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
Cached News: